Bio-Thera Out-Licenses Golimumab To Russia And CIS
Represents Foray Into ‘Important Market’
With a number of next wave candidates in its pipeline, China’s Bio-Thera Solutions has licensed one of them, golimumab, to Russian player Pharmapark, ahead of a global Phase III trial later this year.
You may also be interested in...
Bio-Thera is collaborating with BeiGene for BAT1706, a biosimilar to Avastin (bevacizumab), to develop, manufacture and commercialize the product in Greater China.
Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.
An approval for Innovent’s bevacizumab biosimilar has been granted in China, while other potential rivals to Avastin in the region have hit development milestones.